Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases. The collaboration will engage Charles River (CRL) to utilize Logica, a platform offering from Valo Health, a Flagship-founded company, to identify advanceable small molecule leads. Logica translates biological insights into optimized preclinical assets by leveraging Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading drug discovery expertise. This agreement represents the sixth collaboration signed under the broader strategic partnership between Flagship Pioneering and Pfizer to create a new pipeline of innovative assets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer announces European Commission approval of Abrysvo indication extension
- Pfizer’s Strategic Adaptation to Part D Redesign Drives Buy Rating
- Pfizer’s Strong Financial Performance and Strategic Developments Drive Buy Rating
- Hold Rating Maintained for Pfizer Amid Revenue Concerns and Limited Catalysts
- Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History”